Insider · CIK 0001779805

Young Jonathan

CIK 0001779805 Name as filed on the most recent filing

Filed as Young Jonathan (42)

57 transaction lines · from 42 filings · filed 2021-01-06 to 2025-10-03 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

57 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2025-10-01 S, Open-market sale Akero Therapeutics, Inc.AKRO 2 lines 596,978, disposed Open Form 4 filing 0001193125-25-230294
2025-09-11 S, Open-market sale Akero Therapeutics, Inc.AKRO 25,210, disposed Open Form 4 filing 0000950170-25-114666
2025-09-02 S, Open-market sale Akero Therapeutics, Inc.AKRO 3 lines 576,035, disposed Open Form 4 filing 0001779805-25-000007
2025-08-12 S, Open-market sale Akero Therapeutics, Inc.AKRO 2 lines 597,326, disposed Open Form 4 filing 0000950170-25-108234
2025-06-18 S, Open-market sale Akero Therapeutics, Inc.AKRO 79,683, disposed Open Form 4 filing 0000950170-25-088635
2025-06-10 S, Open-market sale Akero Therapeutics, Inc.AKRO 134,605, disposed Open Form 4 filing 0000950170-25-085667
2025-03-12 S, Open-market sale Akero Therapeutics, Inc.AKRO 27,242, disposed Open Form 4 filing 0000950170-25-039745
2025-03-04 S, Open-market sale Akero Therapeutics, Inc.AKRO 2 lines 2,243,213, disposed Open Form 4 filing 0000950170-25-033998
2025-02-03 S, Open-market sale Akero Therapeutics, Inc.AKRO 2 lines 538,061, disposed Open Form 4 filing 0000950170-25-014188
2025-01-02 S, Open-market sale Akero Therapeutics, Inc.AKRO 280,330, disposed Open Form 4 filing 0000950170-25-001850
2024-12-10 S, Open-market sale Akero Therapeutics, Inc.AKRO 77,067, disposed Open Form 4 filing 0000950170-24-136023
2024-12-02 S, Open-market sale Akero Therapeutics, Inc.AKRO 321,310, disposed Open Form 4 filing 0000950170-24-133434
2024-11-01 S, Open-market sale Akero Therapeutics, Inc.AKRO 3 lines 1,601,252, disposed Open Form 4 filing 0000950170-24-121102
2024-10-14 S, Open-market sale Akero Therapeutics, Inc.AKRO 1,206,080, disposed Open Form 4 filing 0000950170-24-115139
2024-10-01 S, Open-market sale Akero Therapeutics, Inc.AKRO 281,770, disposed Open Form 4 filing 0000950170-24-112672
2024-09-10 S, Open-market sale Akero Therapeutics, Inc.AKRO 14,870, disposed Open Form 4 filing 0000950170-24-106473
2024-09-03 S, Open-market sale Akero Therapeutics, Inc.AKRO 2 lines 133,588, disposed Open Form 4 filing 0000950170-24-103986
2024-08-01 S, Open-market sale Akero Therapeutics, Inc.AKRO 2 lines 133,756, disposed Open Form 4 filing 0000950170-24-090257
2024-07-01 S, Open-market sale Akero Therapeutics, Inc.AKRO 117,020, disposed Open Form 4 filing 0000950170-24-080921
2024-06-11 S, Open-market sale Akero Therapeutics, Inc.AKRO 56,965, disposed Open Form 4 filing 0000950170-24-073192
2024-06-03 S, Open-market sale Akero Therapeutics, Inc.AKRO 96,440, disposed Open Form 4 filing 0000950170-24-069416
2024-05-01 S, Open-market sale Akero Therapeutics, Inc.AKRO 100,750, disposed Open Form 4 filing 0000950170-24-052445
2024-04-01 S, Open-market sale Akero Therapeutics, Inc.AKRO 2 lines 121,913, disposed Open Form 4 filing 0000950170-24-041407
2024-03-13 S, Open-market sale Akero Therapeutics, Inc.AKRO 18,443, disposed Open Form 4 filing 0000950170-24-032262
2023-12-27 S, Open-market sale Akero Therapeutics, Inc.AKRO 129,936, disposed Open Form 4 filing 0000899243-23-020714
2023-12-14 S, Open-market sale Akero Therapeutics, Inc.AKRO 11,273, disposed Open Form 4 filing 0000950170-23-071245
2023-11-17 S, Open-market sale Akero Therapeutics, Inc.AKRO 440,259, disposed Open Form 4 filing 0000950170-23-065611
2023-10-02 S, Open-market sale Akero Therapeutics, Inc.AKRO 25,039, disposed Open Form 4 filing 0000950170-23-052052
2023-09-13 S, Open-market sale Akero Therapeutics, Inc.AKRO 28,291, disposed Open Form 4 filing 0000950170-23-049762
2023-06-13 S, Open-market sale Akero Therapeutics, Inc.AKRO 29,676, disposed Open Form 4 filing 0000899243-23-015669
2023-01-03 S, Open-market sale Akero Therapeutics, Inc.AKRO 479,560, disposed Open Form 4 filing 0000899243-23-001028
2022-12-27 S, Open-market sale Akero Therapeutics, Inc.AKRO 619,609, disposed Open Form 4 filing 0000899243-22-039460
2022-10-25 S, Open-market sale Akero Therapeutics, Inc.AKRO 558,944, disposed Open Form 4 filing 0000899243-22-034371
2021-11-04 S, Open-market sale Akero Therapeutics, Inc.AKRO 151,333, disposed Open Form 4 filing 0001104659-21-135039
2021-11-03 S, Open-market sale Akero Therapeutics, Inc.AKRO 455,791, disposed Open Form 4 filing 0001104659-21-135039
2021-09-01 S, Open-market sale Akero Therapeutics, Inc.AKRO 300,500, disposed Open Form 4 filing 0001104659-21-112970
2021-06-01 S, Open-market sale Akero Therapeutics, Inc.AKRO 80,151, disposed Open Form 4 filing 0001104659-21-075727
2021-05-03 S, Open-market sale Akero Therapeutics, Inc.AKRO 93,361, disposed Open Form 4 filing 0001104659-21-060961
2021-04-01 S, Open-market sale Akero Therapeutics, Inc.AKRO 87,828, disposed Open Form 4 filing 0001104659-21-046655

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
Relationships on this page
O, Officer
Officer

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 0
  • Open-market sale 57
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Young Jonathan, insider transactions. Retrieved 2026-08-22 from https://ebomi.com/insider/0001779805

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.